Comparative Pharmacology
Head-to-head clinical analysis: SCANDONEST L versus XYLOCAINE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SCANDONEST L versus XYLOCAINE PRESERVATIVE FREE.
SCANDONEST L vs XYLOCAINE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Scandonest L (mepivacaine hydrochloride) is an amide-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx across the membrane, thereby blocking nerve impulse initiation and conduction.
Lidocaine stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking impulse initiation and conduction. It binds to voltage-gated sodium channels in the inactivated state, preventing depolarization and propagation of action potentials.
Dental infiltration or nerve block: 1.3 mL of 3% solution (isocaine) per site; maximum 9 mg/kg (0.3 mL/kg) per session. Infiltration: 0.5-1.0 mL; nerve block: 1.0-1.3 mL.
Adult dose: 1-30 mL of 1% or 2% solution (10-600 mg) via subcutaneous infiltration, peripheral nerve block, or epidural; max 4.5 mg/kg (300 mg without epinephrine, 7 mg/kg [500 mg] with epinephrine) per 2-hour period.
None Documented
None Documented
Terminal elimination half-life is 1.5–2.0 hours in healthy adults; prolonged to 3–5 hours in patients with hepatic impairment or severe renal disease.
Terminal elimination half-life approximately 1.5-2 hours in adults; prolonged in hepatic impairment (up to 3-4 hours) and congestive heart failure.
Primarily hepatic metabolism (approx. 90%) via amidase hydrolysis and aromatic hydroxylation; renal excretion of unchanged drug accounts for <5% of the dose; less than 1% excreted in feces.
Renal excretion of metabolites (90-95% as metabolites, <5% unchanged); biliary/fecal excretion minimal (<1%).
Category C
Category C
Local Anesthetic
Local Anesthetic